文献速递胸部PET

PET在切除的IA期非小细胞肺癌中的预后价值

Prognostic value of positron emission tomography in resected stage IA non-small cell lung cancer.
PubMed 文献 · Eur Radiol · 2021-03-25

该研究回顾性分析了998例手术切除肺癌患者,其中637例病理I期患者分为IA1(251例)、IA2(250例)和IA3(136例)。多变量Cox回归显示,磨玻璃影比例(HR=0.001)和肿瘤SUVmax独立预测IA3期NSCLC术后复发风险,SUVmax>4的HR为8.986(p<0.001)。IA1、IA2、IA3期的5年OS率分别为87.2%、92.9%、82.7%,5年DFS率分别为93.2%、84.2%、70.51%(均p<0.001)。

要点

  • IA3期NSCLC中,SUVmax>4提示术后复发风险显著增高(HR=8.986,p<0.001)。
  • 磨玻璃影比例和SUVmax是IA3期NSCLC术后复发的独立预测因素。
  • IA3期且SUVmax>4的患者5年OS和DFS均较差,可考虑术后治疗。

关键影像表现/征象

  • 磨玻璃影比例和肿瘤SUVmax独立预测IA3期NSCLC术后复发风险。
  • SUVmax>4预测复发风险的HR为8.986(p<0.001)。

诊断标准与关键数值

  • SUVmax>4时,IA3期NSCLC复发风险HR为8.986(p<0.001)。
  • 5年OS率:IA1期87.2%、IA2期92.9%、IA3期82.7%(p<0.001)。
  • 5年DFS率:IA1期93.2%、IA2期84.2%、IA3期70.51%(p<0.001)。
  • IA3期NSCLC中,SUVmax>4组 vs ≤4组:5年OS率71.0% vs 92.2%,5年DFS率50.2% vs 87.3%(均p=0.001)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate the role of PET in predicting the prognosis of resected stage IA non-small cell lung cancer (NSCLC) and planning individualized therapeutic strategies.

METHODS: We retrospectively reviewed the data of patients who underwent surgical resection for lung cancer between January 2004 and December 2014. The clinical data, imaging characteristics of nodules, surgical approaches, and outcomes were analyzed.

RESULTS: We evaluated 998 cases; 637 patients with pathological stage I disease were categorized as follows: stage IA1 (251 cases), stage IA2 (250 cases), and stage IA3 (136 cases). The mean follow-up period was 109 months. Significant differences were observed in sex, tumor differentiation, epidermal growth factor receptor mutation, smoking habits, lymphovascular space invasion, tumor size, maximum standard uptake value (SUVmax), and carcinoembryonic antigen level among the groups. Multivariable Cox regression revealed that ground-glass opacity ratio (hazard ratio (HR) = 0.001) and tumor SUVmax independently predicted the postoperative risk of relapse for stage IA3 NSCLC. The HR for SUVmax > 4 was 8.986 (p < 0.001). The 5-year overall survival (OS) rates were 87.2%, 92.9%, and 82.7%, and the 5-year disease-free survival (DFS) rates were 93.2%, 84.2%, and 70.51% for stage IA1, IA2, and IA3 NSCLC, respectively (both p < 0.001). OS and DFS rates were poor in stage IA3 NSCLC patients with an SUVmax uptake > 4 (OS, 71.0% and 92.2%; DFS, 50.2% and 87.3%, for SUVmax > 4 and ≤ 4, respectively; both p = 0.001).

CONCLUSIONS: SUVmax was a prognostic factor for resected stage IA NSCLC. Postoperative treatment may be considered for IA3 NSCLC with SUVmax > 4.

KEY POINTS: • PET helps surgeons to assess patients with early-stage lung cancer. • This retrospective study revealed that PET plays an influential role in predicting the prognosis of resected lung cancer. • Better prognostication aids better planning of therapeutic strategies with diversification.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Chou HP, Lin KH, Huang HK, et al. Prognostic value of positron emission tomography in resected stage IA non-small cell lung cancer. Eur Radiol. 2021. PMID: 33763721. doi:10.1007/s00330-021-07801-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。